Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus

doi:10.3748/wjg.v24.i12.1353

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7547)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

514

WORD

288

HTML

3290

Figures (1-1)

341

Tables (1-3)

250

Sum=4683

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1104

Download

1760

Sum=2864

Mar 28, 2018 (publication date) through Jan 3, 2025

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Mar 28, 2018; 24(12): 1353-1360
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1353

Table 1 Baseline characteristics of study cohort n (%)

Characteristic		Data
Sex	Male	28 (71.8)
	Female	11 (28.2)
Age (yr)		58.6 (range: 45.8-72.3)
Immunosuppression	Cyclosporine	19 (48.7)
	Tacrolimus	18 (46.2)
	Sirolimus	1 (2.6)
	Everolimus	1 (2.6)
	Mycophenolate mofetil	21 (53.8)
Liver histology	F0-2	7 (17.9)
	F3	15 (38.5)
	F4	17 (43.6)
Liver function, CTP	A	17 (43.6)
	B	2 (5.1)
Risk factors	Interferon-experienced	29 (74.4)
	History of HCC	26 (66.7)
HCV genotype	1	24 (61.5)
	2	1 (2.6)
	3	13 (33.3)
	4	1 (2.6)

CTP: Child-turcotte-pugh; HCC: Hepatocellular carcinoma.

Table 2 Hepatitis C virus treatment regimens

n	Therapy	SVR24
5	IFN + SOF + RBV	4/5 (80.0%)
8	SOF + RBV	6/8 (75.0%)
9	DAC +SOF + RBV	9/9 (100.0%)
1	DAC + SOF	1/1 (100.0%)
13	LDV + SOF + RBV	13/13 (100.0%)
2	LDV + SOF	2/2 (100.0%)
1	SIM + SOF + RBV	1/1 (100.0%)

DAC: Daclatasvir; IFN: Interferon; LDV: Ledipasvir; RBV: Ribavirin; SIM: Simeprevir; SOF: Sofosbuvir; SVR24: Sustained virological response at 24 wk.

Table 3 Viral load throughout treatment period

Time (wk)	Mean	Min	Max
T (0)	3268770	45600	25200000
T (4)	25812.1	0	771000
T (8)	22.8	0	268
T (12)	4.1	0	101
T (24)	0	0	0

Citation: Rupp C, Hippchen T, Neuberger M, Sauer P, Pfeiffenberger J, Stremmel W, Gotthardt DN, Mehrabi A, Weiss KH. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus. World J Gastroenterol 2018; 24(12): 1353-1360
URL: https://www.wjgnet.com/1007-9327/full/v24/i12/1353.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i12.1353